Drugmaker-funded science isn’t always more likely to favor new medicines than studies paid for by non-profits, according to a new report on past research in rheumatoid arthritis. The finding flies in the face of a large body of evidence showing industry studies tend to promote new drugs and downplay potential side effects.
